Longsys Founder Bets Big on R&D to Ride AI Memory Wave
THE SO WHAT
Longsys earmarking 78% of proceeds for R&D to move from module house to memory brand shows how AI demand is pulling component makers up the stack. If you depend on commodity memory pricing, model more volatility — differentiated AI-optimized SKUs will command margin while generic parts see sharper cycles.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechJapan’s GMO Internet Requests Government Cyber Defense Measures
A private operator asking the Japanese government for active cyber defense is another data point that large-scale breaches are outgrowing what individual firms can handle alone. If you run critical infrastructure or large consumer platforms, assume more state involvement in incident response and plan governance and disclosure accordingly.
Deep & Emerging TechWe take a tour of HPE’s Technology Renewal Centre to see how old tech is getting a second life
Enterprise hardware is starting to look more like a circular asset class—HPE’s renewal pipeline turns decommissioned gear into a structured supply source. Infra leaders should factor certified refurbished into their capacity planning, especially for non-cutting-edge workloads where capex and lead times matter more than bleeding-edge performance.
Deep & Emerging TechThe UK plans to invest £100M to create the AI Biosecurity Lab to boost defenses against biological threats, supported by OpenAI, Anthropic, and Google DeepMind
AI labs are being pulled directly into national biosecurity architecture — £100M for the UK’s AIBL formalizes that AI capability is now part of biodefense infrastructure. If you touch biology, data, or models, expect tighter scrutiny on dual-use risk and more demand for auditable safety controls baked into your stack.
Deep & Emerging TechUK Vows £100 Million for Biosecurity Lab With OpenAI, Anthropic
A £100M AI Biosecurity Lab with OpenAI, Anthropic, and Google DeepMind formalizes bio-risk as a first-class AI policy and research domain. Healthcare, biotech, and cloud vendors touching biological data should expect more pre-clearance, audits, and specialized guardrails baked into deals and APIs.